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Introduction
Hypoplastic left heart syndrome (HLHS) is characterised by underdevelopment of the left-sided cardiac structures, variably including hypoplasia or atresia of the left ventricle, ascending aorta, and aortic and mitral valves. HLHS is the commonest cause of heart transplantation in infancy and is the cardiovascular malformation most frequently resulting in childhood death (without surgical intervention, HLHS is invariably fatal). There is a substantial familial predisposition to HLHS [1] [2] [3] , though it is not usually a Mendelian condition and first degree relatives of probands with HLHS have a high incidence (11%, versus 1-2% in the general population) of bicuspid aortic valve. Despite this, only a minority of neonates with severe obstruction of left ventricular outflow have HLHS. Diminished flow through the left side of the heart 1,2 and disruption of genetic networks specific to left ventricular chamber development [4] [5] [6] [7] have been suggested to cause HLHS. In particular it has been hypothesised that disruption of genetic networks specific to the left ventricular chamber, which depend on the differential expression of such genes as Tbx5 and Lrx1, is also contributory to the pathogenesis of the condition and loss-of-function mutations in the gene HAND1, which is expressed in left-sided cardiac structures including the LV myocardium, are present in a proportion of patients with HLHS. One report has noted that HLHS patient cardiac myocytes show inappropriate expression of PECAM-1 (CD31) and indications that the HLHS left ventricle has a gene expression pattern reminiscent of a heart failure or fetal gene expression pattern 8 . As yet however, there is relatively little evidence in favour of the role of CMspecific factors in HLHS risk. We have derived iPSC lines from one HLHS patient who demonstrated mild facial dysmorphism, bilateral hip dislocation, hypoplastic fingernails, mild microcephaly, aortic atresia and mitral atresia who subsequently died at 10 days of age. CM differentiated from these lines show substantial differences to those obtained from hESC 9 4 and control-iPSC lines derived from unaffected neonatal human dermal fibroblast (NHDF), supporting the hypothesis that patient specific myocardial developmental factors make a substantial contribution to the development of HLHS.
Materials and methods
Cell source: Dermal fibroblasts derived from the skin biopsy of one HLHS patient (GM12601) were obtained from the Coriell Institute for Medical Research. The patient was clinically diagnosed with hypoplastic left heart syndrome characterised by aortic and mitral atresia. Associated malformations included mild facial dysmorphism, bilateral hip dislocation, hypoplastic fingernails, and mild microcephaly. The patient died ten days after birth.
Derivation, culture and characterisation of human iPSC lines was performed using a polycistronic lentiviral system (Allele Biotech) 10 . 
Results and Discussion
Two iPSC clones were derived from one HLHS patient and one unaffected control.
Both HLHS clones behaved very similarly so the data are presented as the average of the two clones wherever possible. iPSC derivation efficiency was lower for HLHS (0.0002%) than control-iPSC (0.3%). A recent paper that was published while this manuscript was under review has shown the prevalence of a senescent phenotype in HLHS derived CM and endothelial cells 13 . If this was to be true for fibroblasts derived from HLHS patients, it could explain the low efficiency of iPSC derivation as suggested by Marion et al. 14 ,
All resulting iPSC were highly similar to hESC (H9) ( Figure 1A ). Exogenous transgenes were silenced in all pluripotent iPSC lines ( Figure 1B ). All HLHS iPSC lines were karyotypically normal ( Figure 1C ) and isogenic with the parent fibroblasts (Suppl. (Figure 2A) . Sub-cutaneous injection of HLHS-and control-iPSC into immunocompromised NOD/SCID mice gave rise to teratomas containing tissues derived from all three embryonic germ layers ( Figure 2B ). These results demonstrated that fully reprogrammed iPSC can be derived from HLHS patients.
We differentiated hESC, HLHS-and control-iPSC lines into CM using protocols published by Keller's group 11 . We were particularly interested in investigating the differences between HLHS and patient CM as they emerged during human embryonic development and for this reason we focused our studies on the first 21 days of iPSC and ESC 7 differentiation which has been reported by a large number of studies to be sufficient for cardiac commitment and generation of contracting CM. Contracting clusters containing cells expressing cardiac markers such as α-actinin, cardiac troponin (cTnT) and the early cardiac development transcription factor HAND1 15 , could be readily detected by immunohistochemistry from day 10 of differentiation ( Figure 3A) . Quantitative RT-PCR analysis during differentiation suggested that HLHS-iPSC, control-iPSC and hESC downregulated pluripotency markers as shown by SOX2 ( Figure 3B ) and NANOG expression (Suppl. Figure 2A ) and formed mesoderm indicated by expression of BRACHYURY ( Figure   3B ). We noticed a lower expression of a key marker of cardiac mesoderm, MESP1 at differentiation day 10 ( During this study, we have not observed significant differences between iPSC clones derived either from the unaffected control or the HLHS patients. Furthermore, we have not observed significant differences between the H9 human ESC lines and the unaffected control, which lead us to speculate that differences observed between control and HLHS patient are due to the HLHS phenotype rather than intra and inter line variability. It is also encouraging to Figure 4B ). In fully differentiated cardiac muscle, the sarcoplasmic reticulum is the major source of Ca 2+ required for contraction 20, 21 . HLHS-iPSC derived CM generate calcium transients in the presence of caffeine whereas control-iPSC derived CM do not (Suppl. Figure 4C ) implying ryanodine receptor dysfunction in HLHS-iPSC derived CM. The contractile areas are still able to beat so an alternative source of calcium such as the inositol triphosphate system may be operative.
This is indicated by upregulation of IP3R expression in HLHS derived CM compared to control CM (Suppl. Figure 5 ). Multi-electrode array studies of contracting areas also support 10 sarcoplasmic reticulum dysfunction. Treatment of CM with the β1/β2 adrenergic receptor agonist isoproterenol normally increases the contraction frequency by enhancing Ca
2+
ATPase activity in the sarcoplasmic reticulum 22 ; however, the beat frequency of HLHS-iPSC derived CM increases only by 9% after isoproterenol treatment compared to 66% for hESC derived CM (Suppl. Figure 6 ). Therefore, it is possible that for HLHS, inositol triphosphate plays an important role in generating calcium transients. This is also an indicator of immature cardiac differentiation. Set against these data is the observation that control-iPSC derived CM only demonstrate 20% increase in beat frequency; however the inability of HLHS-iPSC derived CM to increase their beat frequency is significant.
Summary:
We have presented data describing the derivation of two iPSC lines from an HLHS patient and demonstrated that CM derived from these lines show developmental and/or functional defects that could compromise their ability to contribute to cardiogenesis in vivo. Our observations of such intrinsic cellular defects correlate with the findings of other groups such as the possibility that gene expression programs more typical of a fetal cardiac phenotype may persist in HLHS-iPSC-derived CM. Further studies are needed to determine if these defects are causative of HLHS not least of which will be the need to derive more patient specific iPSC to address questions of patient genetic background outside the factors responsible for the HLHS phenotype. Differentiation of HLHS-iPSC to CM is a valuable tool in this investigation since it permits examination not only the more mature stages of CM development but also allows us to access several of the cardiac mesoderm cell types that precede CM formation which is not possible from the HLHS patient tissues alone.
Comparison of the transcriptomic and functional parameters of such cells will be a useful mechanism through which we may identify candidate genes whose mutations may contribute to the HLHS phenotype. Suppl. Table 2 . The sequence of oligonucleotides used for the mutation screening analysis. 
Gene

Teratoma formation
Approximately 5x10 5 NHDF-derived-iPSC, HLHS-patient-specific iPSC and hESC were injected subcutaneously into the right flanks of adult NOD/SCID mice and maintained for 6-12 weeks. All cells were co-transplanted with 50µl Matrigel (BD Biosciences) to enhance teratoma formation. After 8 weeks, mice were sacrificed, teratoma tissues were dissected, fixed in Bouins overnight, processed and sectioned according to standard procedures then counterstained with either haematoxylin and eosin or Massons trichrome stain. Sections (5-8µm thick) were examined using bright field light microscopy and photographed as appropriate.
Quantitative RT-PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen) at different points during the differentiation process. Genomic DNA was removed by treatment with DNaseI (Ambion) at 37°C for 30 minutes. Total RNA (1µg) was used for reverse transcription using the SuperScript III First strand synthesis system (Invitrogen). Details of the panel of differentiation markers, cardiac specific markers and calcium handling protein genes are listed in Suppl. Table 1 . Quantitative RT-PCR was performed using an ABI 7900 with the iQ SYBR Green Supermix (Promega). Data was analysed using qBase v1.3.5 and the comparative threshold cycle (Ct) method. In all samples the results were normalised to the expression level of the housekeeping gene GAPDH, and referenced to hESC and human embryonic heart cDNA (obtained from Carnegie Stage 14) depending on the gene of interest being analysed.
EB formation and cardiac differentiation
Before EB formation, the iPSC and hESC were cultured in matrigel-coated plates for 
Immunocytochemical analysis
Undifferentiated iPSC and hESC were plated on 4 well plates under feeder free conditions as described above, whilst single cardiac myocytes were isolated from beating areas using Accutase (Invitrogen) digestion for 10 minutes at 37°C followed by plating onto 0.1% gelatin coated chambers with cardiac medium for 2 days to allow cell attachment. Cells were fixed in 4% paraformaldehyde for 10 minutes at room temperature followed by treatment with 0.5% Triton X-100 for 10 minutes.
Samples were blocked by incubation with 5% BSA for 1 hour at room temperature. All antibodies were checked for specificity on heart sections from human embryos obtained from HDBR (www.hdbr.org).
Flow cytometry
The EB (and/or contractile areas) at different time points were collected and digested with Accutase for 5-7 minutes to obtain a single cell suspension. Cells were washed with PBS and fixed using 4% formaldehyde for 10 minutes followed by permeabilization with methanol for 30 minutes. Samples were incubated with the primary antibodies for 1 hour followed by incubation with an appropriate Alexa fluor 488 conjugated secondary antibody for 30 minutes. DNA staining dye (DAPI) was added before analyzing the samples by flow cytometry (FACS Canto (BD Biosciences, CA, USA). At least 10,000 events were collected and the data was analyzed utilizing FlowJo version 6.4 software. All experiments were performed in triplicate.
DNA fingerprinting
To confirm that HLHS-patient-specific (HLHS1, HLHS2) and unaffected iPSC (NHDF1 and 2) lines were genetically identical to the respective patient dermal fibroblasts, DNA fingerprinting was carried out. Total genomic DNA was extracted from all five samples and amplified with 15 microsatellite markers: D3S1358, TH01, D21S11, D18S51, Penta-E, D5S818, D13S317, D7S820, D16S539, CSF-1PO, Penta-D, vWA, D8S1179, TPOX and FGA and analysed on an ABI 377 sequence detector using Genotype software (Applied Biosystems, Foster City, CA).
Karyotype analysis of HLHS patient specific and unaffected hiPSC
Karyotypes were determined by standard G-banding procedure, as described in
Stojkovic et al 11 .
Transmission electron microscopy
Transmission electron microscopy was performed on day 30 contracting EBs fixed with 2% glutaraldehyde in 0.1M cacodylate buffer. Post fixation was performed at room temperature for 1 hour with 1% osmium and 1.5% postassium ferrocyanide. The samples were dehydrated in graded acetone and embedded in epoxy resin at 60°C.
Half micron sections were stained with 1% toluidine blue and ultra-thin section were cut on Leica EM UC7 ultramicrotome and double stained with 1% uranyl acetate and lead citrate. Ultrastructual examination was performed with Philips CM 100 TEM at 100 kV. Digital images were recorded with an AMT40 CCD camera (Deben).
Measurement of Cytosolic [Ca 2+ ]
Beating clusters were micro-surgically dissected and plated on the gelatine covered 
Multi-electrode array recordings
To characterize the electrophysiological properties of iPSC derived CM, contracting
EBs were dissected and plated on gelatin coated multi-electrode arrays (Multichannel Systems, Reutlingen, Germany) consisting of 60 titanium nitride electrodes (30 µm diameter, 200 µm separation) in a 8x8 configuration without corners. Recordings were performed at a sampling rate of 20 kHz. The recorded electrograms were used to determine the local field potential (FP) duration (FPD). This parameter was previously shown to correlate with the action potential duration and to reflect the local QT interval 12, 13 . To assess the responsiveness of cardiac contractility to badrenoceptor stimulation, 20µL of isoproterenol (Sigma) was added directly to the recording chamber (2 mL volume). Extracellular recordings were performed for 200 seconds in control conditions and at 5 minutes after drug application.
DNA sequencing of cardiac specific genes
Coding regions of NKX2.5, HAND1 and HAND2 genes from HLHS-patient-specific fibroblasts and iPSC, including exon-intron boundaries were amplified by polymerase chain reaction (PCR) of genomic DNA and sequenced. The sequences of oligonucleotides used for this analysis are shown in Suppl. Table 2 . PCR was undertaken for 5'-UTR and 3'-UTR of exons 799bp and 938bp of HAND1, exons 563bp and 1397bp of NKX2.5, and exons 61bp, 107bp, 1288bp and 2150bp of HAND2. Neonatal human diploid fibroblasts (NHDF) and NHDF-derived-iPSC were analysed as controls. PCR products were sequenced commercially (GATC Biotech;
www.gatc-biotech.com) and analysed manually to identify sequence differences between the HLHS patient DNA and the one obtained from unaffected control (NHDF).
